Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas
- PMID: 17303488
- DOI: 10.1016/j.contraception.2006.11.004
Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas
Abstract
Background: A prospective cohort study was carried out to evaluate uterine volume and the volume of uterine leiomyomas in women using the levonorgestrel intrauterine system (LNG-IUS) to treat idiopathic menorrhagia (n=32) and menorrhagia due to leiomyomas (n=27). A control group used the device as a contraceptive method (n=28).
Methods: Clinical and ultrasonographic evaluations were carried out at insertion and at 3, 6, 12, 24 and 36 months later. Total uterine volume and the volume of the leiomyomas were calculated using the ellipsoid formula (anteroposterior diameter)x(transverse diameter)x(longitudinal diameter)x(4/3)x(pi). In the case of multiple leiomyomas, the volume of each myoma was added to calculate the total volume of leiomyomas in each patient. Menstrual bleeding episodes were recorded.
Results: Uterine volume decreased significantly in both groups of menorrhagic patients but not in the control group. In the group of women with idiopathic menorrhagia, a mean reduction of 36.4+/-15.3 (S.D.) cm3 (from 127.1 cm3 to 90.7 cm3) was observed (p=.041), and a greater and more significant mean reduction of 63.6+/-19.0 (S.D.) cm3 (from 156.6 cm3 to 93 cm3) occurred in the group of women with leiomyomas (p=.014). In the contraception group, the reduction was of only 2.9+/-5.4 (S.D.) cm3 in mean uterine volume (from 70.3 cm3 to 67.4 cm3), which was not statistically significant (p=.085). The mean volume of leiomyomas decreased by 5.2+/-3.1 (S.D.) cm3 (from 12.8 cm3 to 7.6 cm3 after 3 years of use, but this difference was not significant (p=.4099). After 36 months of use, amenorrhea and oligomenorrhea were the most frequent bleeding patterns, occurring in 45-57% and 33-39% of users in the three groups, respectively. Amenorrhea was higher in the contraception group (57.1%) and in women with idiopathic menorrhagia (53.4%) than women in the group with menorrhagia due to leiomyomas (44.5%) (p=.027). Moreover, the prevalence of spotting was almost three times higher (11%) in women with menorrhagia caused by leiomyomas and nearly double (7.7%) in the idiopathic menorrhagia group when compared with 4% in the control contraception group (p=.024).
Conclusion: The LNG-IUS significantly reduces uterine volume in women with menorrhagia with and without leiomyoma; however, it does not significantly reduce the volume of leiomyomas.
Comment in
-
Re-checking your work: the formula for success.Contraception. 2007 Oct;76(4):334; author reply 334. doi: 10.1016/j.contraception.2007.03.015. Epub 2007 Jul 26. Contraception. 2007. PMID: 17900448 No abstract available.
Similar articles
-
Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.Eur J Contracept Reprod Health Care. 2001 Jun;6(2):93-101. Eur J Contracept Reprod Health Care. 2001. PMID: 11518454
-
The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study.J Minim Invasive Gynecol. 2008 Nov-Dec;15(6):735-8. doi: 10.1016/j.jmig.2008.08.011. J Minim Invasive Gynecol. 2008. PMID: 18971138
-
[The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].Minerva Ginecol. 2002 Jun;54(3):271-8. Minerva Ginecol. 2002. PMID: 12063443 Italian.
-
Progestin-releasing intrauterine systems and leiomyoma.Contraception. 2007 Jun;75(6 Suppl):S130-3. doi: 10.1016/j.contraception.2007.01.012. Epub 2007 Mar 9. Contraception. 2007. PMID: 17531604 Review.
-
The levonorgestrel intrauterine system: the benefits of reduced bleeding.Eur J Contracept Reprod Health Care. 2001 Jan;6 Suppl 1:27-32. Eur J Contracept Reprod Health Care. 2001. PMID: 11336431 Review.
Cited by
-
U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.MMWR Recomm Rep. 2024 Aug 8;73(4):1-126. doi: 10.15585/mmwr.rr7304a1. MMWR Recomm Rep. 2024. PMID: 39106314 Free PMC article.
-
Updated approaches for management of uterine fibroids.Int J Womens Health. 2017 Sep 5;9:607-617. doi: 10.2147/IJWH.S138982. eCollection 2017. Int J Womens Health. 2017. PMID: 28919823 Free PMC article. Review.
-
Tailoring the Diagnostic Pathway for Medical and Surgical Treatment of Uterine Fibroids: A Narrative Review.Diagnostics (Basel). 2024 Sep 14;14(18):2046. doi: 10.3390/diagnostics14182046. Diagnostics (Basel). 2024. PMID: 39335725 Free PMC article. Review.
-
The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review.Drugs. 2012 Jan 22;72(2):193-215. doi: 10.2165/11598960-000000000-00000. Drugs. 2012. PMID: 22268392 Review.
-
The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids.Prz Menopauzalny. 2017 Dec;16(4):129-132. doi: 10.5114/pm.2017.72758. Epub 2017 Dec 30. Prz Menopauzalny. 2017. PMID: 29483855 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous